{
    "root": "3596cce0-efa0-258a-e063-6294a90acfc3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Testosterone",
    "value": "20250520",
    "ingredients": [
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "TESTOSTERONE",
            "code": "3XMK78S47O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17347"
        },
        {
            "name": "CARBOMER 980",
            "code": "4Q93RCW27E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15649"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "ISOPROPYL MYRISTATE",
            "code": "0RE8K4LNJS",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13966"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "testosterone gel , 1.62 % indicated replacement therapy adult males conditions associated deficiency absence endogenous testosterone : primary hypogonadism ( congenital acquired ) : testicular failure due conditions cryptorchidism , bilateral torsion , orchitis , vanishing testis syndrome , orchiectomy , klinefelter 's syndrome , chemotherapy , toxic damage alcohol heavy metals . men usually low serum testosterone concentrations gonadotropins ( follicle-stimulating hormone [ fsh ] , luteinizing hormone [ lh ] ) normal range . hypogonadotropic hypogonadism ( congenital acquired ) : gonadotropin luteinizing hormone releasing hormone ( lhrh ) deficiency pituitary-hypothalamic injury tumors , trauma , radiation . men low testosterone serum concentrations , gonadotropins normal low range . limitations : safety efficacy testosterone gel , 1.62 % men \u201c age-related hypogonadism \u201d ( also referred \u201c late-onset hypogonadism \u201d ) established . safety efficacy testosterone gel , 1.62 % males less 18 years old established [ ( 8.4 ) ] . topical testosterone products may different doses , strengths , application instructions may result different systemic exposure [ usage ( 1 ) , pharmacology ( 12.3 ) ] .",
        "doid_entities": [
            {
                "text": "hypogonadism (DOID:1924)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1924"
            },
            {
                "text": "cryptorchidism (DOID:11383)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11383"
            },
            {
                "text": "orchitis (DOID:2518)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2518"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "hypogonadotropic hypogonadism (DOID:0090070)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0090070"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "testosterone gel , 1.62 % differs testosterone gel , 1 % . testosterone gel , 1 % refer full prescribing information . ( 2 ) prior initiating testosterone gel , 1.62 % , confirm diagnosis hypogonadism ensuring serum testosterone concentrations measured morning least two separate days serum testosterone concentrations normal range .",
        "doid_entities": [
            {
                "text": "hypogonadism (DOID:1924)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1924"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "testosterone gel , 1.62 % supplied non-aerosol , metered-dose pumps deliver 20.25 mg testosterone per complete pump actuation . pumps composed plastic stainless steel ldpe/aluminum foil inner liner encased rigid plastic polypropylene cap . 88 g metered-dose pump capable dispensing 75 g gel 60-metered pump actuations ; pump actuation dispenses 1.25 g gel . ndc number package size 72603-265-01 88 g pump ( pump dispenses 60 metered pump actuations pump actuation containing 20.25 mg testosterone 1.25 g gel ) store controlled room temperature 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . used testosterone gel , 1.62 % pumps discarded household trash manner prevents accidental application ingestion children pets .",
    "adverseReactions": "testosterone gel , 1.62 % contraindicated men carcinoma breast known suspected carcinoma prostate [ ( 5.1 ) ( 6.1 ) ] . testosterone gel , 1.62 % contraindicated women pregnant . testosterone gel , 1.62 % cause virilization female fetus administered pregnant woman . pregnant women need aware potential transfer testosterone men treated testosterone gel , 1.62 % . pregnant woman exposed testosterone gel , 1.62 % , apprised potential hazard fetus [ ( 5.2 ) ( 8.1 ) ] .",
    "indications_original": "Testosterone gel, 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:\n                  \n                     Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.\n                     Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range.\n                  \n                  Limitations of use:\n                  \n                     Safety and efficacy of testosterone gel, 1.62% in men with \u201cage-related hypogonadism\u201d (also referred to as \u201clate-onset hypogonadism\u201d) have not been established.\n                     Safety and efficacy of testosterone gel, 1.62% in males less than 18 years old have not been established\n  \n   [see Use in Specific Populations (\n   \n    8.4)]\n  \n   .\n \n  \n                     Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure\n  \n   [see Indications and Usage (\n                        \n                           1\n                        \n                        ), and Clinical Pharmacology (\n   \n    12.3\n                        \n                        )].",
    "contraindications_original": "Dosage and Administration for testosterone gel, 1.62% differs from testosterone gel, 1%. For dosage and administration of Testosterone Gel, 1% refer to its full prescribing information. (\n  \n   2\n                     \n                     )\n                  \n                  Prior to initiating Testosterone Gel, 1.62%, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.",
    "warningsAndPrecautions_original": "Testosterone gel, 1.62%\u00a0is supplied in non-aerosol, metered-dose pumps that deliver 20.25 mg of testosterone per complete pump actuation. The pumps are composed of plastic and stainless steel and an LDPE/aluminum foil inner liner encased in rigid plastic with a polypropylene cap. Each 88 g metered-dose pump is capable of dispensing 75 g of gel or 60-metered pump actuations; each pump actuation dispenses 1.25 g of gel.\n                  \n                     \n                        \n                           \n                              NDC Number\n                           \n                           \n                              Package Size\n                           \n                        \n                        \n                           72603-265-01\n                           88 g pump (each pump dispenses 60 metered pump actuations with each pump actuation containing 20.25 mg of testosterone in 1.25 g of gel)\n                        \n                     \n                  \n                  Store at controlled room temperature 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Used testosterone gel, 1.62% pumps should be discarded in household trash in a manner that prevents accidental application or ingestion by children or pets.",
    "adverseReactions_original": "Testosterone gel, 1.62% is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate\n  \n   [see Warnings and Precautions (\n   \n    5.1\n                        \n                        ) and Adverse Reactions (\n   \n    6.1\n                        \n                        )].\n                     \n                     Testosterone gel, 1.62% is contraindicated in women who are pregnant. Testosterone gel, 1.62% can cause virilization of the female fetus when administered to a pregnant woman. Pregnant women need to be aware of the potential for transfer of testosterone from men treated with testosterone gel, 1.62%. If a pregnant woman is exposed to testosterone gel, 1.62%, she should be apprised of the potential hazard to the fetus\n  \n   [see Warnings and Precautions (\n   \n    5.2) and Use in Specific Populations (\n   \n    8.1)]\n  \n   .",
    "drug": [
        {
            "name": "Testosterone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17347"
        }
    ]
}